Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FP-1039/GSK3052230, a protein therapeutic, which is in Phase 1b clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, a Phase 1 clinical trial stage antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumo...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Total Annual Compensation: $525.0K
Chief Business Officer
Total Annual Compensation: $362.8K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $350.0K
Senior Vice President
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2013.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 03:55 PM
Dec 4 14
Five Prime Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 03:55 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Julie Hambleton, Chief Medical Officer and Senior Vice President, Lewis T. Williams, Founder, Chief Executive Officer, President and Director.
Five Prime Therapeutics, Inc. Initiates Dosing in its Phase 1 Clinical Trial of FPA144
Dec 4 14
Five Prime Therapeutics, Inc. announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b (FGFR2b) and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC). FPA144 is being developed initially as a monotherapy for refractory gastric cancer, a significant unmet medical need that may warrant an accelerated development and registration path. The Phase 1 clinical trial of FPA144 has two parts. The first part of the trial will enroll unselected patients with solid tumors to explore the safety of the drug and identify a dose for expansion to test in patients with gastric cancer. During the second part of the trial, Five Prime will enroll gastric cancer patients with FGFR2b protein overexpression or FGFR2 gene amplification in their tumors as identified through proprietary molecular diagnostic assays. Important endpoints of the trial include safety and overall response rate.
Bristol-Myers Squibb Company Enters into Clinical Collaboration Agreement with Five Prime Therapeutics, Inc
Dec 2 14
Bristol-Myers Squibb Company (BMS), and Five Prime Therapeutics, Inc. have entered into a clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combination of Opdivo, BMS's investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor, or CSF1R, in six tumor types. The phase Ia/Ib study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma. Opdivo and FPA008 are part of a new class of cancer treatments known as immunotherapies that are designed to harness the body's own immune system to fight cancer. Opdivo is approved in Japan for the treatment of patients with unresectable melanoma, and is being developed in multiple tumor types in more than 50 clinical trials.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 19, 2014